Home・Список акций・MannKind Corp

MannKind Corp

Открыт

СекторЗдравоохранение

4.11 3.79

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

3.89

Макс.

4.09

Ключевые показатели
By Trading Economics
Доход	-671K -17M
Продажи	-22M 90M
P/E Средняя по отрасли	140.5 68.51
Прибыль на акцию	-0.02
Рентабельность продаж	-18.431
Сотрудники	591
EBITDA	5M 2.5M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+120.96% upside

Дивиденды
By Acuity
Следующий отчет о доходах	5 авг. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	306M 1.2B
Предыдущая цена открытия	0.32
Предыдущая цена закрытия	4.11

Новостные настроения

By Acuity

59%

41%

288 / 340 Рейтинг в Healthcare

MannKind Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

4 авг. 2026 г., 23:26 UTC

MannKind Corp shares are lower in after-market hours, with no specific news identified to explain the price movement. Trading has remained within a narrow range.

3 авг. 2026 г., 22:51 UTC

MannKind Corp shares are higher in after-market trading, reflecting momentum since Monday's close amid falling Brent crude oil prices and positive market sentiment.

31 июл. 2026 г., 23:56 UTC

MannKind Corp shares traded lower in after-market hours, retreating from earlier gains. The stock remains near the lower end of its one-month range.

30 июл. 2026 г., 18:41 UTC

Event

News

Wells Fargo raised MannKind's price target to $14.00, contributing to positive momentum. The company also reported favorable Phase 1b study results today.

29 июл. 2026 г., 19:47 UTC

News

Event

MannKind Corp reported positive results from its Phase 1b INFLO-1 study, but shares are trading lower amid broader market uncertainty ahead of the Fed's decision.

28 июл. 2026 г., 21:01 UTC

News

MannKind Corp will report its second quarter 2026 financial results on August 5, 2026. Shares are trading higher in after-market hours.

27 июл. 2026 г., 22:06 UTC

MannKind Corp shares are higher in after-market trading, despite earlier declines. No specific news was identified to explain the price movement.

24 июл. 2026 г., 21:01 UTC

Event

MannKind Corp shares are rising in after-market trading following FDA approval of Furoscix ReadyFlow™ for treating edema in heart failure and chronic kidney disease.

23 июл. 2026 г., 10:36 UTC

MannKind Corp shares are higher in pre-market trading, continuing an upward trend since Wednesday, despite declines in the broader tech sector.

22 июл. 2026 г., 21:01 UTC

MannKind Corp shares are higher in after-market trading, reflecting a gain since Wednesday's close, despite remaining below the 20-day moving average.

21 июл. 2026 г., 22:11 UTC

MannKind Corp shares rose in after-market trading, reflecting a broader rebound in technology stocks and strong interest in semiconductor and AI investments.

Сравнение c конкурентами

Изменение цены

MannKind Corp Прогноз

Целевая цена

By TipRanks

120.96% рост

Прогноз на 12 месяцев

Средняя 8.75 USD 120.96%

Максимум 14 USD

Минимум 4.75 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для MannKind Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

6 ratings

Покупка

Удержание

Продажа

Основано на мнении 6 аналитиков, присваивавших рейтинги акциям MannKind Corp – Данные за последние 3 месяца.

Настроения

By Acuity

288 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.